insitro vs Verge Genomics (2026)
Two machine learning drug discovery companies that both refuse to learn from the usual proxies. insitro generates its own multimodal cellular data through stem cell models, genome editing and high content imaging, then learns causal biology from data it created rather than data it found, with its core method in peer review. Verge goes further in one direction, building an all in human platform on a proprietary library of patient tissue, which targets the specific reason neurology programmes fail: mouse models that do not translate. Verge has also taken a molecule into human study, which insitro has not disclosed. Both should be asked the same uncomfortable question, which is whose tissue the platform learned from, because a target discovered in one population is not automatically a target in another and neither publishes cohort composition.
- The data is generated in house rather than mined from public sources, converging stem cell models, genome editing and high content imaging so the platform produces the biology it learns from.
- The core method was submitted to peer review rather than described in marketing terms, which is the standard this index rewards and few in this category meet.
- Capital structure is disclosed with useful precision, which for a private company at this scale tells a partner something about runway and staying power.
- The platform is all in human, built on a proprietary library of multi omic patient tissue rather than on animal or cell line proxies, which addresses the translation failure that kills most neurology programmes.
- Deal architecture is unusually well disclosed for a private company, so a prospective partner can see the shape of the relationship before entering it.
- It has taken a molecule through investigational new drug status into human study, which is a milestone most platforms in this category have not reached.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. insitro and Verge Genomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | insitro | Verge Genomics |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2018 | 2015 |
| Headquarters | South San Francisco, CA | South San Francisco, California, United States |
| Website | insitro.com | vergegenomics.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards insitro its top capability grade on AI Centrality and Model and Technology Transparency. Set against Verge Genomics, insitro grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Verge Genomics its top capability grade on AI Centrality. Set against insitro, Verge Genomics does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose insitro or Verge Genomics?
The AI Health Index grades insitro higher than Verge Genomics on every axis that separates them, several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Verge Genomics does not grade higher on any scored axis.
Where do insitro and Verge Genomics differ most?
The widest separation the AI Health Index records between insitro and Verge Genomics is on Model Supply Chain Disclosure, where insitro grades B and Verge Genomics grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do insitro and Verge Genomics grade the same?
The AI Health Index grades insitro and Verge Genomics the same on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have insitro and Verge Genomics not disclosed?
At the last review, at least one of insitro and Verge Genomics published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both operate on human derived data, which makes the governance question here cohort composition rather than model architecture: a platform learning from tissue collected in particular populations will find targets that matter for those populations, and neither vendor publishes the demographic composition of its data. Ask for it directly. Neither publishes a security attestation or trust centre.
Platform evidence and clinical evidence should be held apart on both records: peer reviewed method work says the approach is sound, while an asset clearing human trials says the approach produced a drug, and only the second is what a partner is ultimately buying.